2026 Healthcare Safety 
Pharmaceutical Technology
JULY 26, 2022
The SPAC is sponsored by a Frazier Healthcare Partners affiliate. Through an oversubscribed and upsized private investment in public equity (PIPE) led jointly by Frazier Healthcare Partners and Bain Capital Life Sciences, the combined business is expected to receive nearly $235m and funds held in the trust account of FLAC.
pharmaphorum
OCTOBER 14, 2022
The four devices will be put through their paces in real-world healthcare settings via pilot projects in Norway, Belgium, Slovenia, Spain, and Germany. The project started on 1 October and is scheduled to complete in September 2026. Great to have you on board @ForumWeee , we look forward to the next four years of collaboration! .”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
MARCH 24, 2023
Regulatory science refers to the scientific disciplines that are applied to the quality, safety and efficacy assessment of medicinal products. Thus, regulators needed to be ready to support the development and assessment of ever more complex medicines that increasingly deliver healthcare solutions by converging different technologies.
Infuse Medical
JULY 4, 2024
VR in healthcare is doing magic by transforming the conventional working environment to the next level. Brief Overview of the Importance of Medical Device Maintenance Medical device maintenance ensures patient safety, operational efficiency, and regulatory compliance in healthcare settings. What is VR Training?
European Pharmaceutical Review
SEPTEMBER 26, 2023
Multiple sclerosis is a chronic condition with no cure at present and timely access to affordable, high-quality healthcare is therefore even more essential.” Both studies confirmed that the biosimilar matched the reference biologic for pharmacokinetics as well as efficacy, safety and immunogenicity.
Clarivate
OCTOBER 25, 2023
The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.
pharmaphorum
JULY 26, 2022
Merck’s exit came after other companies including Pfizer, Eli Lilly and Roche all scrapped CETP development programmes following safety or efficacy issues. BROADWAY and BOOKLYN will generate data in 2024, with PREVAIL set to read to in 2026, and if the results are positive will be followed by filings in the US, Europe, China and Japan.
Expert insights. Personalized for you.
59 
Let's personalize your content